According to the latest CPHI Annual Survey, CDMOs will see a significant increase in demand for biologic therapy manufacturing. With the tailwinds of pandemic-related manufacturing capacity expansion, CDMO sales will rise from $120.6 billion last year to $171.3 billion in 2026, with a focus on specialty drugs, growth in nuclear medicine, advances in cell and gene therapies ($12.4 billion in 2026) and single-use devices ($20.8 billion in 2026). But live microbial therapies, antibody conjugates, nanoswitches and protein degraders are also expected to expand. New and cost-efficient processes and streamlined supply are seen as success factors of the future. Contract manufacturers that have all capacities in-house or specialised CDMOs are predicted to have good opportunities in emerging markets.
Topics to be covered
Sustainability: The new imperative
Shift towards industrial-scale AAV manufacturing
Tackling pharma’s footprint
Interview: György Rajkai, CTO, Belach Bioteknik AB
High value process development